GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MetaStat Inc (OTCPK:MTST) » Definitions » Shiller PE Ratio

MetaStat (MetaStat) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2008. Start your Free Trial

What is MetaStat Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MetaStat Shiller PE Ratio Historical Data

The historical data trend for MetaStat's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MetaStat Shiller PE Ratio Chart

MetaStat Annual Data
Trend Feb09 Feb10 Feb11 Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MetaStat Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MetaStat's Shiller PE Ratio

For the Biotechnology subindustry, MetaStat's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MetaStat's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MetaStat's Shiller PE Ratio falls into.



MetaStat Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

MetaStat's E10 for the quarter that ended in Feb. 2018 is calculated as:

For example, MetaStat's adjusted earnings per share data for the three months ended in Feb. 2018 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Feb. 2018 (Change)*Current CPI (Feb. 2018)
=-0.17/105.0520*105.0520
=-0.170

Current CPI (Feb. 2018) = 105.0520.

MetaStat Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200805 -2.100 91.399 -2.414
200808 -4.500 92.435 -5.114
200811 -4.500 89.624 -5.275
200902 -1.500 89.527 -1.760
200905 0.000 90.228 0.000
200908 0.000 91.063 0.000
200911 0.000 91.272 0.000
201002 -1.350 91.445 -1.551
201005 -1.050 92.052 -1.198
201008 -0.600 92.108 -0.684
201011 -0.600 92.315 -0.683
201102 -8.879 93.373 -9.990
201105 0.450 95.337 0.496
201108 -0.150 95.582 -0.165
201111 -0.300 95.449 -0.330
201202 -0.750 96.053 -0.820
201205 -0.300 96.961 -0.325
201208 -0.600 97.199 -0.648
201211 -0.450 97.133 -0.487
201302 -0.450 97.953 -0.483
201305 -1.200 98.282 -1.283
201308 -0.750 98.675 -0.798
201311 -0.750 98.334 -0.801
201402 -1.200 99.057 -1.273
201405 -0.900 100.373 -0.942
201408 -2.505 100.352 -2.622
201411 -0.790 99.635 -0.833
201502 -0.660 99.032 -0.700
201505 -1.210 100.333 -1.267
201508 -0.730 100.548 -0.763
201511 -0.720 100.135 -0.755
201602 -0.630 100.040 -0.662
201605 -1.080 101.355 -1.119
201608 -0.460 101.617 -0.476
201611 -1.160 101.829 -1.197
201702 0.109 102.779 0.111
201705 -0.060 103.256 -0.061
201708 -0.160 103.587 -0.162
201711 -0.210 104.072 -0.212
201802 -0.170 105.052 -0.170

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MetaStat  (OTCPK:MTST) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


MetaStat Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of MetaStat's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MetaStat (MetaStat) Business Description

Traded in Other Exchanges
N/A
Address
27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Executives
Daniel H Schneiderman officer: VP OF FINANCE AND SECRETARY 760 PARKSIDE AVE. SUITE 304, SUITE 207, BROOKLYN NY 11226
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Paul Billings director 11055 FLINTKOTE AVENUE, SUITE B, SAN DIEGO CA 92121
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Martin J Driscoll director C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Oscar Bronsther director 4 AUTUMNWOOD COURT, THE WOODLANDS TX 77380
Johan M. Spoor director 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
David N Siegel director T-S CAPITAL PARTNERS, LLC, 1350 TREAT BOULEVARD, SUITE 400, WALNUT CREEK CA 94597
Warren C Lau director 2635 N. CRESCENT RIDGE DRIVE, THE WOODLANDS TX 77381
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
David M. Epstein director OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Richard W Perkins 10 percent owner 730 EAST LAKE STREET, WAYZATA MN 55391
Harvey Judkowitz director 10220 SW 124 ST, MIAMI FL 33176

MetaStat (MetaStat) Headlines

No Headlines